VEGFA and cancer: Consistent with the aforementioned direct anti-angiogenic effects, a further investigation identified the hexahydrocannabinol analogues LYR-7 [(9S)-3,6,6,9-tetramethyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1-ol] and LYR-8 [(1-((9S)-1-hydroxy-6,6,9-trimethyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-2-yl)ethanone)] as inhibitors of VEGF-induced proliferation, migration and capillary-like tube formation of human endothelial cells as well as VEGF-induced blood vessel formation in the chorioallantoic membrane assay and VEGF release from cancer cells [122].